Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma

Emmanouilides, Christos; Rosen, Peter J.; Telatar, Milhan; Malone, Rubie M.; Bosserman, Linda D.; Menco, Harry; Patel, Ravi; Barstis, John; Grody, Wayne W.

doi:10.3816/clm.2000.n.013

Cited by 11 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of 27 patients, 20 achieved a complete response and 5 achieved a partial response, for an overall response rate of 92%. 52 A 100% overall response rate with a 58% complete remission rate was reported by Czuczman et al 53 combining rituximab with CHOP. Similar data also emerged from studies by Howard et al 31 and Rambaldi et al 54 Maloney et al 55 applied rituximab as maintenance therapy with similar results and a PFS of 76% at 2 years.…”

Section: Discussionmentioning

confidence: 86%

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Forstpointner¹,

Dreyling²,

Repp³

et al. 2004

Blood

540

257

View full text Add to dashboard Cite

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Of 128 evaluable patients, 62 were randomized for FCM and 66 for R-FCM. R-FCM revealed an overall response rate of 79% (33% complete remission [CR], 45% partial remission [PR]) as compared with 58% for FCM alone (13% CR, 45% PR; P ‫؍‬ .01), with similar results in a subgroup analysis of FL (94% vs 70%) and MCL (58% vs 46%). In the total group, the R-FCM arm was significantly superior concerning progression-free survival (PFS; P ‫؍‬ .0381) and overall survival (OS; P ‫؍‬ .0030). In FL PFS was significantly longer in the R-FCM arm (P ‫؍‬ .0139) whereas in MCL a significantly longer OS was observed (P ‫؍‬ .0042). There were no differences in clinically relevant side effects in both study arms. Hence, the addition of rituximab to FCM chemotherapy significantly improves the outcome of relapsed or refractory FL and MCL. (Blood.

show abstract

Section: Discussionmentioning

confidence: 86%

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Forstpointner¹,

Dreyling²,

Repp³

et al. 2004

Blood

540

257

View full text Add to dashboard Cite

show abstract

Mitoxantrone–cyclophosphamide–rituximab: an effective and safe combination for indolent NHL

Emmanouilides¹,

Territo²,

Menco³

et al. 2003

Hematological Oncology

View full text Add to dashboard Cite

Treatment for extensive indolent lymphoma should combine optimization of efficacy without excessive toxicity. Rituxan may be an ideal agent for combinations with chemotherapy because of its non-cross-resistant toxicity profile and the potential for synergism. We present the results of 32 patients with indolent B-cell NHL who received a novel three-drug combination designed with the intent of preservation of both efficacy and quality of life. Patient characteristics were as follows, median age, 58 years (36-75 years); histology, follicular 16, SLL/CLL five, lymphoplasmacytic six, marginal cell five; relapsed or refractory, 10; untreated, 22. Patients first received cyclophosphamide 800 mg/m(2) and mitoxantrone 8 mg/m(2), iv on the same day, every 3 weeks for two cycles. Subsequently, patients received rituximab followed by mitoxantrone 8 mg/m(2) every 2 weeks for four cycles. The regimen, and particularly rituximab, was extremely well tolerated. Grade I/II, infusion-related toxicity was noted in 10%. Six patients achieved a PR and 23 a CR for an overall response of 90% (95% CI: 79-100%). The actuarial median TTP for all patients was 30 months. Molecular remissions were noted in 8/14 patients tested in CR. We conclude that the cyclophosphamide-mitoxantrone-rituxan (CyMiR) regimen is effective and extremely well tolerated. Furthermore, rituximab infusion-related morbidity is nearly completely eliminated.

show abstract

Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma

Hong

Kim

Ahn

et al. 2012

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma

Cited by 11 publications

References 23 publications

Mitoxantrone–cyclophosphamide–rituximab: an effective and safe combination for indolent NHL

Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma

Contact Info

Product

Resources

About